A Detailed Assessment of Varying Ejection Rate on Delivery Efficiency of Mesenchymal Stem Cells Using Narrow‐Bore Needles

As the number of clinical trials exploring cell therapy rises, a thorough understanding of the limits of cell delivery is essential. We used an extensive toolset comprising various standard and multiplex assays for the assessment of cell delivery postejection. Primary human mesenchymal stem cell (hMSC) suspensions were drawn up into 100‐µl Hamilton syringes with 30‐ and 34‐gauge needles attached, before being ejected at rates ranging from 10 to 300 µl/minute. Effects of ejection rate, including changes in viability, apoptosis, senescence, and other key aspects of cellular health, were evaluated. Ejections at slower flow rates resulted in a lower percentage of the cell dose being delivered, and apoptosis measurements of samples ejected at 10 µl/minute were significantly higher than control samples. Immunophenotyping also revealed significant downregulation of CD105 expression in samples ejected at 10 µl/minute (p < .05). Differentiation of ejected hMSCs was investigated using qualitative markers of adipogenesis, osteogenesis, and chondrogenesis, which revealed that slower ejection rates exerted a considerable effect upon the differentiation capacity of ejected cells, thereby possibly influencing the success of cell‐based therapies. The findings of this study demonstrate that ejection rate has substantial impact on the percentage of cell dose delivered and cellular health postejection.

[1]  K. Shakesheff,et al.  The effect of injection using narrow‐bore needles on mammalian cells: administration and formulation considerations for cell therapies , 2015, The Journal of pharmacy and pharmacology.

[2]  N. Kasim,et al.  Advancing stem cell therapy from bench to bedside: lessons from drug therapies , 2014, Journal of Translational Medicine.

[3]  Jian-Ping Chen,et al.  Daucosterol promotes the proliferation of neural stem cells , 2014, The Journal of Steroid Biochemistry and Molecular Biology.

[4]  M. Chopp,et al.  Human Placenta-Derived Adherent Cell Treatment of Experimental Stroke Promotes Functional Recovery after Stroke in Young Adult and Older Rats , 2014, PloS one.

[5]  K. Rudolph,et al.  Enhanced telomere rejuvenation in pluripotent cells reprogrammed via nuclear transfer relative to induced pluripotent stem cells. , 2014, Cell stem cell.

[6]  J. Xie,et al.  A Two-Year Follow-Up Study of Cotransplantation with Neural Stem/Progenitor Cells and Mesenchymal Stromal Cells in Ischemic Stroke Patients , 2014, Cell transplantation.

[7]  A. Bahnassy,et al.  Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease , 2014, Stem Cell Research & Therapy.

[8]  Yongjun Jiang,et al.  Feasibility of Delivering Mesenchymal Stem Cells via Catheter to the Proximal End of the Lesion Artery in Patients with Stroke in the Territory of the Middle Cerebral Artery , 2013, Cell transplantation.

[9]  Jia Wei,et al.  Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles. , 2013, Biomaterials.

[10]  G. D. de Freitas,et al.  The rise of cell therapy trials for stroke: review of published and registered studies. , 2013, Stem cells and development.

[11]  Xia Chen,et al.  Effect of DMSO concentration, cell density and needle gauge on the viability of cryopreserved cells in three dimensional hyaluronan hydrogel , 2013, 2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC).

[12]  Yu-fang Shi,et al.  Mesenchymal stem cells: a new trend for cell therapy , 2013, Acta Pharmacologica Sinica.

[13]  Joshua M Hare,et al.  Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. , 2012, JAMA.

[14]  A. Das,et al.  Impact of passing mesenchymal stem cells through smaller bore size needles for subsequent use in patients for clinical or cosmetic indications , 2012, Journal of Translational Medicine.

[15]  J. Glass,et al.  Lumbar Intraspinal Injection of Neural Stem Cells in Patients with Amyotrophic Lateral Sclerosis: Results of a Phase I Trial in 12 Patients , 2012, Stem cells.

[16]  L. Rosenberg,et al.  Ex Vivo Expansion of Human Mesenchymal Stem Cells in Defined Serum-Free Media , 2012, Stem cells international.

[17]  S. Savitz,et al.  Intra-arterial delivery of cell therapies for stroke. , 2012, Stem cells and development.

[18]  Brian A. Aguado,et al.  Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers. , 2012, Tissue engineering. Part A.

[19]  D. Kondziolka,et al.  Injection Parameters Affect Cell Viability and Implant Volumes in Automated Cell Delivery for the Brain , 2011, Cell transplantation.

[20]  C. Borlongan,et al.  Baby STEPS: A Giant Leap for Cell Therapy in Neonatal Brain Injury , 2011, Pediatric Research.

[21]  B. Gersh,et al.  CD34(+) cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent. , 2011, American heart journal.

[22]  Shinil K. Shah,et al.  Effect of needle diameter and flow rate on rat and human mesenchymal stromal cell characterization and viability. , 2010, Tissue engineering. Part C, Methods.

[23]  Joshua M Hare,et al.  A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. , 2009, Journal of the American College of Cardiology.

[24]  C. Cowan,et al.  Transcatheter Injection-Induced Changes in Human Bone Marrow-Derived Mesenchymal Stem Cells , 2009, Cell transplantation.

[25]  E. Miljan,et al.  Stem cell treatment of ischemic brain injury. , 2009, Current opinion in molecular therapeutics.

[26]  L. Isola,et al.  Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  Seong Who Kim,et al.  Down-regulation of CD105 is associated with multi-lineage differentiation in human umbilical cord blood-derived mesenchymal stem cells. , 2009, Biochemical and biophysical research communications.

[28]  Jeffrey M Karp,et al.  Mesenchymal stem cell homing: the devil is in the details. , 2009, Cell stem cell.

[29]  A. Caplan.  Why are MSCs therapeutic? New data: new insight , 2009, The Journal of pathology.

[30]  K. Shakesheff,et al.  The effect of delivery via narrow-bore needles on mesenchymal cells. , 2009, Regenerative medicine.

[31]  Arnold P. G. Hoeks,et al.  Wall shear stress as measured in vivo: consequences for the design of the arterial system , 2008, Medical & Biological Engineering & Computing.

[32]  E. Ayyıldız,et al.  Comparison of different needle diameters and flow rates on bone marrow mononuclear stem cell viability: an ex vivo experimental study. , 2008, Cytotherapy.

[33]  D. Prockop,et al.  Concise Review: Mesenchymal Stem/Multipotent Stromal Cells: The State of Transdifferentiation and Modes of Tissue Repair—Current Views , 2007, Stem cells.

[34]  B. Min,et al.  Complete Spinal Cord Injury Treatment Using Autologous Bone Marrow Cell Transplantation and Bone Marrow Stimulation with Granulocyte Macrophage‐Colony Stimulating Factor: Phase I/II Clinical Trial , 2007, Stem cells.

[35]  L. Dušek,et al.  Autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction: the effect of the dose of transplanted cells on myocardial function. , 2006, American heart journal.

[36]  D. Shum-Tim,et al.  Massive mechanical loss of microspheres with direct intramyocardial injection in the beating heart: implications for cellular cardiomyoplasty. , 2006, The Journal of thoracic and cardiovascular surgery.

[37]  T. Schallert,et al.  Transplantation of hNT neurons into the ischemic cortex: Cell survival and effect on sensorimotor behavior , 2006, Journal of neuroscience research.

[38]  S. Gronthos,et al.  Mesenchymal lineage precursor cells induce vascular network formation in ischemic myocardium , 2006, Nature Clinical Practice Cardiovascular Medicine.

[39]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[40]  A. Dagher,et al.  Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. , 2005, Brain : a journal of neurology.

[41]  D. Kondziolka,et al.  Evaluation of Surgical Techniques for Neuronal Cell Transplantation Used in Patients with Stroke , 2004, Cell transplantation.

[42]  M. Yacoub,et al.  Role of Interleukin-1&bgr; in Acute Inflammation and Graft Death After Cell Transplantation to the Heart , 2004, Circulation.

[43]  D. Kondziolka,et al.  Evaluation of surgical techniques for neuronal cell transplantation used in patients with stroke. , 2004, Cell transplantation.

[44]  Larry Kedes,et al.  Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. , 2002, Journal of molecular and cellular cardiology.

[45]  S. Alper,et al.  Hemodynamic shear stress and its role in atherosclerosis. , 1999, JAMA.

[46]  J. Mills,et al.  Extranuclear Apoptosis: The Role of the Cytoplasm in the Execution Phase , 1999 .